‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug.

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug

Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.